OncoTEX Inc., an oncology company of the iQ Group Global, and Sterling Pharma Solutions, a global CDMO, signed a clinical development agreement for the manufacture of OncoTex’s novel platinum-resistant oncology drug candidate, OxaliTEX, for use in clinical trials.   Sterling will produce clinical material in its cGMP facility in Germantown, WI, which has the capabilities to handle highly potent active pharmaceutical ingredients (HPAPIs) in fully contained manufacturing suites.   OxaliTEX is ...